431 related articles for article (PubMed ID: 9053440)
1. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.
van der Merwe PA; Bodian DL; Daenke S; Linsley P; Davis SJ
J Exp Med; 1997 Feb; 185(3):393-403. PubMed ID: 9053440
[TBL] [Abstract][Full Text] [Related]
2. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions.
Greene JL; Leytze GM; Emswiler J; Peach R; Bajorath J; Cosand W; Linsley PS
J Biol Chem; 1996 Oct; 271(43):26762-71. PubMed ID: 8900156
[TBL] [Abstract][Full Text] [Related]
3. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
Linsley PS; Greene JL; Brady W; Bajorath J; Ledbetter JA; Peach R
Immunity; 1994 Dec; 1(9):793-801. PubMed ID: 7534620
[TBL] [Abstract][Full Text] [Related]
4. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
5. Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28.
Peach RJ; Bajorath J; Naemura J; Leytze G; Greene J; Aruffo A; Linsley PS
J Biol Chem; 1995 Sep; 270(36):21181-7. PubMed ID: 7545666
[TBL] [Abstract][Full Text] [Related]
6. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.
Fargeas CA; Truneh A; Reddy M; Hurle M; Sweet R; Sékaly RP
J Exp Med; 1995 Sep; 182(3):667-75. PubMed ID: 7544393
[TBL] [Abstract][Full Text] [Related]
7. Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.
Lazetic S; Leong SR; Chang JC; Ong R; Dawes G; Punnonen J
J Biol Chem; 2002 Oct; 277(41):38660-8. PubMed ID: 12167647
[TBL] [Abstract][Full Text] [Related]
8. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies.
Murata K; Dalakas MC
Am J Pathol; 1999 Aug; 155(2):453-60. PubMed ID: 10433938
[TBL] [Abstract][Full Text] [Related]
9. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells.
Caux C; Vanbervliet B; Massacrier C; Azuma M; Okumura K; Lanier LL; Banchereau J
J Exp Med; 1994 Nov; 180(5):1841-7. PubMed ID: 7525840
[TBL] [Abstract][Full Text] [Related]
10. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses.
Zhang YQ; Joost van Neerven RJ; Van Gool SW; Coorevits L; de Boer M; Ceuppens JL
Int Immunol; 1997 Aug; 9(8):1095-102. PubMed ID: 9263006
[TBL] [Abstract][Full Text] [Related]
11. The CD28/CTLA-4-B7 signaling pathway is involved in both allergic sensitization and tolerance induction to orally administered peanut proteins.
van Wijk F; Nierkens S; de Jong W; Wehrens EJ; Boon L; van Kooten P; Knippels LM; Pieters R
J Immunol; 2007 Jun; 178(11):6894-900. PubMed ID: 17513738
[TBL] [Abstract][Full Text] [Related]
12. Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules.
Linsley PS; Nadler SG; Bajorath J; Peach R; Leung HT; Rogers J; Bradshaw J; Stebbins M; Leytze G; Brady W
J Biol Chem; 1995 Jun; 270(25):15417-24. PubMed ID: 7541042
[TBL] [Abstract][Full Text] [Related]
13. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28.
Metzler WJ; Bajorath J; Fenderson W; Shaw SY; Constantine KL; Naemura J; Leytze G; Peach RJ; Lavoie TB; Mueller L; Linsley PS
Nat Struct Biol; 1997 Jul; 4(7):527-31. PubMed ID: 9228944
[TBL] [Abstract][Full Text] [Related]
14. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
Lane P
Ann N Y Acad Sci; 1997 Apr; 815():392-400. PubMed ID: 9186685
[TBL] [Abstract][Full Text] [Related]
15. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN
Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604
[TBL] [Abstract][Full Text] [Related]
16. In silico engineering a CD80 variant with increased affinity to CTLA-4 and decreased affinity to CD28 for optimized cancer immunotherapy.
Hajihassan Z; Afsharian NP; Ansari-Pour N
J Immunol Methods; 2023 Feb; 513():113425. PubMed ID: 36638881
[TBL] [Abstract][Full Text] [Related]
17. In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity.
Denfeld RW; Dietrich A; Wuttig C; Tanczos E; Weiss JM; Vanscheidt W; Schöpf E; Simon JC
Int J Cancer; 1995 Jul; 62(3):259-65. PubMed ID: 7543078
[TBL] [Abstract][Full Text] [Related]
18. The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion.
Rennert P; Furlong K; Jellis C; Greenfield E; Freeman GJ; Ueda Y; Levine B; June CH; Gray GS
Int Immunol; 1997 Jun; 9(6):805-13. PubMed ID: 9199963
[TBL] [Abstract][Full Text] [Related]
19. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion.
Wu Y; Guo Y; Huang A; Zheng P; Liu Y
J Exp Med; 1997 Apr; 185(7):1327-35. PubMed ID: 9104819
[TBL] [Abstract][Full Text] [Related]
20. Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis.
Truneh A; Reddy M; Ryan P; Lyn SD; Eichman C; Couez D; Hurle MR; Sekaly RP; Olive D; Sweet R
Mol Immunol; 1996 Feb; 33(3):321-34. PubMed ID: 8649453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
